Below are the most recently updated broker updates which include ratings and price targets for ADMA Biologics Inc (ADMA).

09/17/2015 – Broker: Maxim Group Rating: buy reiteration

09/09/2015 – Broker: Raymond James Rating: strong-buy New Target: 15 newcoverage

05/18/2015 – Broker: Zacks Rating: buy New Target: 9.5 upgrade

12/08/2014 – Broker: Oppenheimer Rating: outperform New Target: 20 newcoverage

11/18/2013 – Broker: Ladenburg Thalmann Rating: buy New Target: 16 newcoverage

The average price target from the most recent broker reports is 15.12

The stock decreased -3.16% (-0.20) during the last days session, reaching 6.12 and roughly 61297 shares were bought or sold by traders.

View other investors thoughts on ADMA Biologics Inc with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.